{
  "image_filename": "table_p13_det_12_007.png",
  "image_path": "Grohskopf_et_al.__2023_/extracted/figures/table_p13_det_12_007.png",
  "image_type": "Table",
  "page_number": 13,
  "block_id": "det_12_007",
  "claim_id": "claim_002",
  "claim": "Cell- and egg-based flu vaccines have the potential to develop mutations during production, which may reduce their effectiveness.",
  "supports_claim": false,
  "explanation": "A portion of a table listing various quadrivalent influenza vaccines (e.g., Afluria Quadrivalent, Fluarix Quadrivalent, Flucelvax Quadrivalent, etc.), their manufacturers, and recommended dose volumes and hemagglutinin content, along with footnotes and abbreviations relating to dosage volume. The table only provides vaccine names, manufacturers, and dose volumes; it contains no information on production methods, mutation potential, or effectiveness impact, and therefore does not support the claim. Note: Limited to the visible portion of the table, which focuses solely on dosing information.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "A portion of a table listing various quadrivalent influenza vaccines (e.g., Afluria Quadrivalent, Fluarix Quadrivalent, Flucelvax Quadrivalent, etc.), their manufacturers, and recommended dose volumes and hemagglutinin content, along with footnotes and abbreviations relating to dosage volume.",
    "evidence_found": null,
    "reasoning": "The table only provides vaccine names, manufacturers, and dose volumes; it contains no information on production methods, mutation potential, or effectiveness impact, and therefore does not support the claim.",
    "confidence_notes": "Limited to the visible portion of the table, which focuses solely on dosing information."
  }
}